Neuropharmacology Core
神经药理学核心
基本信息
- 批准号:10182736
- 负责人:
- 金额:$ 29.41万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2018
- 资助国家:美国
- 起止时间:2018-08-15 至 2023-05-31
- 项目状态:已结题
- 来源:
- 关键词:AcuteAnimal ModelAntiepileptic AgentsAnxietyAwardBehavioralBindingBiochemicalBiologicalBiological AssayBody TemperatureBusinessesCannabinoidsCatalepsyCell Culture TechniquesCellsCenters for Disease Control and Prevention (U.S.)Centers of Research ExcellenceCharacteristicsCognitionCollaborationsCommunitiesCore FacilityDevelopmentDifferentiation and GrowthEducationEnsureEnzymesEquipmentExperimental DesignsFee-for-Service PlansFeedbackG-Protein-Coupled ReceptorsGoalsGrantIn VitroInfrastructureLeadLeadershipLocomotionMental DepressionMississippiModelingMolecularMonitorMonoamine Oxidase ANatural ProductsNeuraxisNeuronsNeuropharmacologyNeurosciencesNociceptionOpioidPharmacologyPharmacy SchoolsPhasePhenotypePositioning AttributePostdoctoral FellowPropertyPublicationsQuality ControlRattusResearchResearch PersonnelResource SharingRodentScientistServicesSignal PathwayStructureStructure of thyroid parafollicular cellSurveysTechniquesToxic effectTrainingUniversitiesZebrafishbasebehavior testbehavioral pharmacologybiological systemsdrug developmentdrug seeking behavioresteraseexperienceexperimental studyflexibilityin vitro Assayin vivoinstrumentationmeetingsmouse modelmultidisciplinaryneuropeptide FFneuroprotectionneurotoxicityoutreachprogramsradioligandreceptor bindingresponsesynthetic drug
项目摘要
PROJECT SUMMARY/ABSTRACT
The Center of Research Excellence in Natural Products Neuroscience (CORE-NPN) at The University of
Mississippi School of Pharmacy (UM), initiated ten years ago through a COBRE grant, has developed a
multidisciplinary team committed to evaluating the effects of natural products on the central nervous system
(CNS). The Neuropharmacology Research Core of the COBRE CORE-NPN program represents a shared
resource serving biomedical investigators / users with specialized services and training in neuropharmacological
bioassays based on (a) competitive radioligand receptor binding, (b) modulation of molecular/biochemical target
functions (c) cell-based phenotypic & functional responses and (d) in vivo behavioral pharmacology. This was
originally two Cores, in vitro and in vivo pharmacology, in Phases I and II, with strong utilization by investigators
and strong collaboration between the two. In Phase III, it has been determined that these Cores would best serve
the program as one functional unit. Furthermore, by the end of Phase III, the Core is projected to be largely
sustainable with efforts focused on understanding neuropharmacological properties of lead biological extracts or
purified compounds and how they interact with biological systems. Efforts have been focused on expanding the
core capabilities by increasing both in vitro and in vivo assays that are available to users, thereby increasing the
numbers of projected users served. A fee-for-service/chargeback business model will be implemented during
Phase III to ensure sustainability post Phase III. Specific Core services include radioligand binding and functional
assays for cannabinoid, opioid, and Neuropeptide FF G protein-coupled receptors (GPCRs), as well as enzyme
assays, phenotypic neuronal cell cultures-based assays, and analysis of neuropharmacological signaling
pathways. Moreover, the Core offers a battery of acute behavioral rodent and zebrafish assays to evaluate
natural product extracts and purified compounds in vivo. New in vitro assays and animal models will continue to
be developed to support user needs, which ultimately broadens the overall scope and user-base for the Core.
The Core is positioned to become a leader in neuropharmacological services based on natural product and
synthetic drug development campaigns. We plan to achieve this through the following Specific Aims: 1) To
enhance the research of the COBRE CORE-NPN and the associated community through state-of-the-art
equipment, cutting-edge techniques, and scientific expertise; 2) To advance an infrastructure of developmental
services to facilitate COBRE CORE-NPN research and the associated community by continual refinement and
addition of assays through user input. 3) To accelerate a long-term plan for sustainability of the Core through
expansion of the user base, integration of a fee-for-service structure, institutional support, and adaptation to
changes by monitoring the needs of the users.
项目摘要/摘要
加州大学天然产物神经科学卓越研究中心(CORE-NPN)
密西西比州药学院(UM),十年前通过科布雷赠款发起,已经开发出一种
致力于评估天然产品对中枢神经系统影响的多学科团队
(CNS)。Cobre CORE-NPN计划的神经药理学研究核心代表着一个共享的
为生物医学研究人员/用户提供专门服务和神经药理学培训的资源
基于(A)竞争性放射性配基受体结合,(B)调节分子/生化靶标的生物测定
功能(C)基于细胞的表型和功能反应以及(D)体内行为药理学。这是
最初两个核心,体外和体内药理学,在第一阶段和第二阶段,由研究人员大力利用
以及两者之间的强有力的合作。在第三阶段,已经确定这些核心将最好地服务于
将程序作为一个功能单元。此外,到第三阶段结束时,核心预计将主要
可持续,重点是了解铅生物提取物或
纯化的化合物以及它们如何与生物系统相互作用。努力的重点是扩大
核心能力,通过增加可供用户使用的体外和体内检测,从而增加
预计服务的用户数。年内将实施按服务收费/按存储容量使用计费的业务模式
第三阶段,以确保第三阶段之后的可持续性。具体核心服务包括放射性配基结合和功能
大麻素、阿片类和神经肽FFG蛋白偶联受体(GPCRs)以及酶的测定
神经药理信号分析、基于表型神经元细胞培养的分析
小路。此外,Core还提供了一系列急性行为啮齿动物和斑马鱼的检测方法,以评估
天然产物提取物和体内纯化的化合物。新的体外测试和动物模型将继续
为支持用户需求而开发,最终扩大了核心的总体范围和用户基础。
核心定位为成为神经药理服务的领导者基于天然产品和
合成药物开发活动。我们计划通过以下具体目标实现这一目标:1)
通过最新技术加强对COBRE CORE-NPN及其相关社区的研究
设备、尖端技术和科学专长;2)推进发展基础设施
通过不断改进和改进,促进Cobre CORE-NPN研究和相关社区的服务
通过用户输入添加化验。3)通过以下方式加快核心可持续性的长期计划
扩大用户基础、整合按服务收费结构、体制支助和适应
通过监控用户的需求进行更改。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
KENNETH J SUFKA其他文献
KENNETH J SUFKA的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('KENNETH J SUFKA', 18)}}的其他基金
MISSISSIPPI COBRE: P4: ID OF REWARDING CONSTITUENTS IN BOTANICAL EXTRACTS
密西西比 COBRE:P4:植物提取物中奖励成分的 ID
- 批准号:
7610760 - 财政年份:2007
- 资助金额:
$ 29.41万 - 项目类别:
MISSISSIPPI COBRE: P4: ID OF REWARDING CONSTITUENTS IN BOTANICAL EXTRACTS
密西西比 COBRE:P4:植物提取物中奖励成分的 ID
- 批准号:
7382240 - 财政年份:2006
- 资助金额:
$ 29.41万 - 项目类别:
相似海外基金
Quantification of Neurovasculature Changes in a Post-Hemorrhagic Stroke Animal-Model
出血性中风后动物模型中神经血管变化的量化
- 批准号:
495434 - 财政年份:2023
- 资助金额:
$ 29.41万 - 项目类别:
Small animal model for evaluating the impacts of cleft lip repairing scar on craniofacial growth and development
评价唇裂修复疤痕对颅面生长发育影响的小动物模型
- 批准号:
10642519 - 财政年份:2023
- 资助金额:
$ 29.41万 - 项目类别:
Bioactive Injectable Cell Scaffold for Meniscus Injury Repair in a Large Animal Model
用于大型动物模型半月板损伤修复的生物活性可注射细胞支架
- 批准号:
10586596 - 财政年份:2023
- 资助金额:
$ 29.41万 - 项目类别:
A Comparison of Treatment Strategies for Recovery of Swallow and Swallow-Respiratory Coupling Following a Prolonged Liquid Diet in a Young Animal Model
幼年动物模型中长期流质饮食后吞咽恢复和吞咽呼吸耦合治疗策略的比较
- 批准号:
10590479 - 财政年份:2023
- 资助金额:
$ 29.41万 - 项目类别:
Diurnal grass rats as a novel animal model of seasonal affective disorder
昼夜草鼠作为季节性情感障碍的新型动物模型
- 批准号:
23K06011 - 财政年份:2023
- 资助金额:
$ 29.41万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Longitudinal Ocular Changes in Naturally Occurring Glaucoma Animal Model
自然发生的青光眼动物模型的纵向眼部变化
- 批准号:
10682117 - 财政年份:2023
- 资助金额:
$ 29.41万 - 项目类别:
A whole animal model for investigation of ingested nanoplastic mixtures and effects on genomic integrity and health
用于研究摄入的纳米塑料混合物及其对基因组完整性和健康影响的整体动物模型
- 批准号:
10708517 - 财政年份:2023
- 资助金额:
$ 29.41万 - 项目类别:
A Novel Large Animal Model for Studying the Developmental Potential and Function of LGR5 Stem Cells in Vivo and in Vitro
用于研究 LGR5 干细胞体内外发育潜力和功能的新型大型动物模型
- 批准号:
10575566 - 财政年份:2023
- 资助金额:
$ 29.41万 - 项目类别:
Elucidating the pathogenesis of a novel animal model mimicking chronic entrapment neuropathy
阐明模拟慢性卡压性神经病的新型动物模型的发病机制
- 批准号:
23K15696 - 财政年份:2023
- 资助金额:
$ 29.41万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
The effect of anti-oxidant on swallowing function in an animal model of dysphagia
抗氧化剂对吞咽困难动物模型吞咽功能的影响
- 批准号:
23K15867 - 财政年份:2023
- 资助金额:
$ 29.41万 - 项目类别:
Grant-in-Aid for Early-Career Scientists